Holland Foundation for Sight Restoration Announces Second Annual Ocular Surface Stem Cell Transplantation Education Conference
The Holland Foundation for Sight Restoration is thrilled to announce its second annual Ocular Surface Stem Cell Transplantation Education Conference, scheduled for Friday and Saturday,...
Emmecell Completes Final Cell Therapy Dosing in U.S. Clinical Trial for Corneal Edema
Emmetrope Ophthalmics LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today announced final...
Ophthalmic Industry Leader Erin Schallhorn Powers Joins Holland Foundation for Sight Restoration Board of Directors
Erin Schallhorn Powers, a seasoned professional with nearly 20 years of experience in the ophthalmic industry, has joined the board of directors of the Holland...
Eye Love Rock N’ Roll Benefit Concert to Support Holland Foundation for Sight Restoration at ASCRS
The Holland Foundation for Sight Restoration is proud to announce, "Eye Love Rock N’ Roll," a benefit concert taking place at 8 p.m. on Sunday,...
Amber Ophthalmics Announces First Patient Enrolled in NEXPEDE-1, a Phase 2/3 Clinical Trial Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defects
Amber Ophthalmics, Inc. (Amber), a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye Specialists has enrolled the first patient...
Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON® for the Treatment of Persistent Corneal Epithelial Defect (PCED)
•• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone •• NEXAGON was well-tolerated demonstrating a...